Study of Dato-DXd as Monotherapy and in Combination With Anti-cancer Agents in Patients With Advanced Solid Tumours (TROPION-PanTumor03)
Endometrial Cancer · Gastric Cancer · Metastatic Castration-resistant Prostate Cancer · Ovarian Cancer · Colorectal Cancer · Urothelial Cancer · Biliary Tract Cancer
No strong warning signs right now. The score counts warning signs; it is not a prediction.
Why this score
No warning signs right now. That's why the score is 0.
Score over time
- Stage
- Phase 2
- Patients
- 454 (planned)
- Started
- Sep 6, 2022
- Main results expected
- Oct 1, 2027
- Fully finished
- Oct 1, 2027
- Results posted
- not yet
What counts as success
The trial's main goal(s), called the “primary outcome.”
Objective response rate (ORR)
Measured over: From baseline to progressive disease or death (approximately 1 year)
The number of subjects with adverse events/serious adverse events
Measured over: Throughout the treatment and the safety follow-up period 28 [+ 7] days after the discontinuation of all study interventions, except durvalumab, nivolumab, and bevacizumab for which it will be 90 [+ 7] days (approximately 1 year)
PSA50 response (Substudy 3 only)
Measured over: From baseline to PSA response evaluated according to the PCWG3 criteria (approximately 1 year)
Progression free survival (PFS) response (Substudy 4C only)
Measured over: From baseline to progressive disease or death (approximately 1 year)
Changes Tremor has spotted
Show details (technical version)
Score inputs
- none
Raw record changes
- none yet
Trial ID NCT05489211 · record last updated 2026-09-23 · checked 2026-11-09 15:47 UTC